Vera Therapeutics, Inc. Stock price

Equities

VERA

US92337R1014

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
49.14 USD +4.38% Intraday chart for Vera Therapeutics, Inc. +3.56% +219.51%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * - Sales 2024 * - Capitalization 2.58B
Net income 2023 * -94M Net income 2024 * -104M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-22.6 x
P/E ratio 2024 *
-23.1 x
Employees 49
Yield 2023 *
-
Yield 2024 *
-
Free-Float 78.89%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vera Therapeutics, Inc.

1 day+4.38%
1 week+3.56%
Current month+4.38%
1 month+25.52%
3 months+255.06%
6 months+165.05%
Current year+219.51%
More quotes
1 week
45.23
Extreme 45.23
50.78
1 month
36.01
Extreme 36.01
50.78
Current year
14.20
Extreme 14.2
50.78
1 year
5.95
Extreme 5.95
50.78
3 years
5.20
Extreme 5.2
50.78
5 years
5.20
Extreme 5.2
50.78
10 years
5.20
Extreme 5.2
50.78
More quotes
Managers TitleAgeSince
Founder 50 16-04-30
Director of Finance/CFO 39 21-07-11
Chief Tech/Sci/R&D Officer - 23-05-03
Members of the board TitleAgeSince
Director/Board Member 67 16-05-31
Chairman 63 22-05-23
Director/Board Member 62 20-10-31
More insiders
Date Price Change Volume
24-03-01 49.14 +4.38% 2,039,118
24-02-29 47.08 +2.48% 931,537
24-02-28 45.94 -4.57% 513,817
24-02-27 48.14 +3.86% 982,306
24-02-26 46.35 -2.32% 842,667

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
49.14 USD
Average target price
31.88 USD
Spread / Average Target
-35.13%
Consensus
  1. Stock
  2. Equities
  3. Stock Vera Therapeutics, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW